Skip to content

US · NRSN · BIOTECHNOLOGY

NeuroSense Therapeutics Ltd. (NRSN) intrinsic value and stock valuation

$1.28as of 2026-11-21 · Mkt cap 19.15M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NeuroSense Therapeutics Ltd. DCF and intrinsic value

InvestorsCraft values NRSN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NRSN’s statements →

NeuroSense Therapeutics Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Herzliya, TA 4672562 neurosense-tx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-11.12M
20192025
Free cash flow
-$-7.68M
20192025
Total equity
-$-1.56M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-11.09M-$-9.9M-$-12.05M-$-13.55M-$-5.59M
Net income-$-11.12M-$-10.21M-$-10.11M-$-12.34M-$-4.04M
EPSd-$-436.42K-$-548.92K-$-741.2K-$-1.07M-$-372.01K
Operating cash flow-$-7.67M-$-10.13M-$-8.35M-$-7.59M-$-1.54M
Capital expenditure-$-10K-$0.00-$-30K-$-70K-$-20K
Free cash flow-$-7.68M-$-10.14M-$-8.38M-$-7.66M-$-1.56M
Total assets$1.03M$4.58M$3.19M$7.71M$11.4M
Total debt$170K$70K$140K$210K$0.00
Net debt$0.00-$-3.31M-$-2.5M-$-3.33M-$-11.06M
Total equity-$-1.56M$2.58M-$-1.76M$5.62M$9.01M
Cash and short-term investments$170K$3.38M$2.64M$7.09M$11.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$90K$0.00
Gross profit$0.00$0.00$0.00-$-90K$0.00
Research and development expenses$6.23M$5.7M$7.27M$6.42M$3.08M
Selling, general and administrative expenses$4.86M$4.2M$4.78M$7.05M$2.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$11.1M$9.9M$12.1M$13.5M$5.59M
Cost and expenses$11.1M$9.9M$12.1M$13.6M$5.59M
Interest income$10K$0.00$180K$90K$0.00
Interest expense$0.00$310K$550K$10K$1.15M
Depreciation and amortization$20K$20K$20K$90K$0.00
Ebitda-$-11.11M-$-9.88M-$-9.64M-$-12.23M-$-2.88M
Operating income-$-11.09M-$-9.9M-$-12.05M-$-13.55M-$-5.59M
Total other income/expenses, net-$-40K-$-310K$1.94M$1.21M$1.55M
Income before tax-$-11.12M-$-10.21M-$-10.11M-$-12.34M-$-4.04M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-11.12M-$-10.21M-$-10.11M-$-12.34M-$-4.04M
Weighted average shares outstanding$25.5M$18.6M$13.6M$11.5M$10.9M
Weighted average diluted shares outstanding$25.5M$18.6M$13.6M$11.5M$10.9M
Balance sheet
20252024202320222021
Cash and short-term investments$170K$3.38M$2.64M$7.09M$11.1M
Net receivables$30K$160K$170K$130K$180K
Inventory$0.00$0.00$0.00$0.00-$-180K
Total current assets$780K$4.4M$2.92M$7.38M$11.4M
Property, plant and equipment, net$230K$150K$250K$310K$20K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$250K$170K$270K$330K$20K
Total assets$1.03M$4.58M$3.19M$7.71M$11.4M
Accounts payable$800K$1.16M$1.46M$500K$40K
Short-term debt$100K$70K$70K$60K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.52M$1.99M$3.46M$1.73M$600K
Long-term debt$70K$0.00$70K$150K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$70K$0.00$1.49M$360K$1.83M
Capital lease obligations$170K$70K$140K$210K$0.00
Total liabilities$2.59M$1.99M$4.94M$2.09M$2.42M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-47.78M-$-36.66M-$-26.12M-$-20.79M-$-8.45M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-1.56M$2.58M-$-1.76M$5.62M$9.01M
Total investments$0.00$0.00$0.00$3.55M$0.00
Total debt$170K$70K$140K$210K$0.00
Net debt$0.00-$-3.31M-$-2.5M-$-3.33M-$-11.06M
Cash flow statement
20252024202320222021
Net income-$-11.12M-$-10.21M-$-10.11M-$-12.34M-$-4.04M
Depreciation and amortization$20K$20K$20K$90K$0.00
Stock-based compensation$2.14M$560K$1.54M$5.11M$4.16M
Change in working capital$1.34M-$-780K$1.91M$750K$270K
Accounts receivable$0.00$0.00$20K$60K-$-200K
Inventory$0.00$0.00$0.00-$-60K$0.00
Accounts payable-$-360K-$-300K$960K$460K-$-20K
Net cash provided by operating activities-$-7.67M-$-10.13M-$-8.35M-$-7.59M-$-1.54M
Investments in property, plant and equipment-$-10K-$0.00-$-30K-$-70K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K$0.00$3.47M-$-3.54M-$-20K
Common stock issued$4.55M$11.3M$3.98M$3.87M$9.86M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.43M$10.9M$3.98M$3.69M$11.9M
Net change in cash-$-3.21M$740K-$-900K-$-7.52M$10.4M
Cash at end of period$170K$3.38M$2.64M$3.54M$11.1M
Operating cash flow-$-7.67M-$-10.13M-$-8.35M-$-7.59M-$-1.54M
Capital expenditure-$-10K-$0.00-$-30K-$-70K-$-20K
Free cash flow-$-7.68M-$-10.14M-$-8.38M-$-7.66M-$-1.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NeuroSense Therapeutics Ltd.

        NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

        CEO
        Alon Ben-Noon
        Employees
        17
        Beta
        1.56

        Explore

        Frequently asked questions

        What is the intrinsic value of NeuroSense Therapeutics Ltd. (NRSN)?

        InvestorsCraft does not currently publish an intrinsic value for NRSN. How the IC value is calculated.

        Is NRSN undervalued?

        InvestorsCraft does not publish an undervaluation signal for NRSN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.